NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

Table 1 Direct-acting antivirals approved or at the computed tomography stage (phase II or III )

NS3/4A protease inhibitors	Polymerase inhibitors		Inhibitors
	Nucleotides/nucleosides	Non-nucleoside	NS5A	Cyclophilin
Generation I: Boceprevir (Merck)1 Telaprevir (Vertex)1	PSI-7977 (Pharmasset)1 PSI-938 (Pharmasset)1 Mericitabine (Roche/ Genentech)1 IDX-184 (Idenix)	Filibuvir (Pfizer)1 VX-222 (Vertex)1 Tegobuvir (Gilead)1 ANA-598 (Anadys)1 ABT-072 (Abbott)1 ABT-333 (Abbott)1	Daclatasvir (Bristol-Myers Squibb) GS-5885 (Gilead)1	Alisporivir (Novartis)1 SCY-635 (Scynexis)1
Generation II: Simeprevir (Tibotec) BI 201335 (Boehringer Ingelheim) Danoprevir (Roche/Genentech), studied with Ritonavir; Vaniprevir (Merck)2 BMS-650032 (Bristol-Myers Squibb)2 GS-9451 (Gilead)1 GS-9256 (Gilead)2 ACH-1625 (Achillion)1 ABT-450 (Abbott) MK-5172 (Merck)1

¹Approved by the United States Food and Drug Administration; phase II CT; phase III CT;

²Not studied. From Short Guide to Hepatitis C 2013, Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H.